Drug Eluting Stent (DES) in Primary Angioplasty (PASEO)
PaclitAxel or Sirolimus-Eluting Stent vs Bare Metal Stent in Primary Angioplasty (PASEO) Randomized Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Avellino, Italy, 83100
- U.O. Cardiologia/UTIC
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical symptoms of STEMI, with initial onset of chest pain within the past 12 hours, an ECG demonstrating > 0.1 mV ST-segment elevation in 2 or more contiguous leads or documented new left bundle-branch block and were suitable candidates for percutaneous revascularization.
Exclusion Criteria:
- Active internal bleeding or a history of bleeding diathesis within the previous 30 days
- An history of intracranial hemorrhage
- Intracranial neoplasm
- Arteriovenous malformation or aneurysm
- Known allergy to sirolimus
- Paclitaxel
- Heparin, aspirin, or clopidogrel
- An history of stroke within 30 days or any history of hemorrhagic stroke
- History, symptoms, or findings suggestive of aortic dissection, fibrinolytic therapy within 24 hours
- History of thrombocytopenia, pregnancy, patients on warfarin or acenocoumarol within the last seven days
- Inability to obtain the informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: A
Patient with ST elevation myocardial infarction randomly assigned to receive a Bare Metal Stent n=90)
|
Open-label randomization was performed after initial angiography by the treating physician when eligibility criteria were met.
All patients received in the CCU 70U/Kg i.v.
bolus of UFH plus 1000U/h infusion (to maintain an ACT of at least 200 seconds), aspirin intravenously (500 mg) and clopidogrel (300 mg loading dose).
All patients received upstream Gp IIb-IIIa inhibitors administration as a routine adjunctive therapy before primary PCI.
Postinterventional antiplatelet therapy for all patients included in the three study group, consisted of aspirin (100 mg) indefinitely and clopidogrel (75 mg for six months).
Stenting procedures were performed according to standard techniques.
The number and length of stents, and the type of BMS to be implanted, were left to the operator's discretion.
The operator was allowed to implant DES to cover the entire length of the lesion with coverage of the entire stented segment and of 5 mm proximal and distal segments.
Other Names:
|
|
Experimental: B
Patient with ST elevation myocardial infarction randomly assigned to receive a Paclitaxel Eluting Stent (n=90)
|
Open-label randomization was performed after initial angiography by the treating physician when eligibility criteria were met.
All patients received in the CCU 70U/Kg i.v.
bolus of UFH plus 1000U/h infusion (to maintain an ACT of at least 200 seconds), aspirin intravenously (500 mg) and clopidogrel (300 mg loading dose).
All patients received upstream Gp IIb-IIIa inhibitors administration as a routine adjunctive therapy before primary PCI.
Postinterventional antiplatelet therapy for all patients included in the three study group, consisted of aspirin (100 mg) indefinitely and clopidogrel (75 mg for six months).
Stenting procedures were performed according to standard techniques.
The number and length of stents, and the type of BMS to be implanted, were left to the operator's discretion.
The operator was allowed to implant DES to cover the entire length of the lesion with coverage of the entire stented segment and of 5 mm proximal and distal segments.
Other Names:
|
|
Experimental: C
Patient with ST elevation myocardial infarction randomly assigned to receive a Sirolimus Eluting Stent (n=90)
|
Open-label randomization was performed after initial angiography by the treating physician when eligibility criteria were met.
All patients received in the CCU 70U/Kg i.v.
bolus of UFH plus 1000U/h infusion (to maintain an ACT of at least 200 seconds), aspirin intravenously (500 mg) and clopidogrel (300 mg loading dose).
All patients received upstream Gp IIb-IIIa inhibitors administration as a routine adjunctive therapy before primary PCI.
Postinterventional antiplatelet therapy for all patients included in the three study group, consisted of aspirin (100 mg) indefinitely and clopidogrel (75 mg for six months).
Stenting procedures were performed according to standard techniques.
The number and length of stents, and the type of BMS to be implanted, were left to the operator's discretion.
The operator was allowed to implant DES to cover the entire length of the lesion with coverage of the entire stented segment and of 5 mm proximal and distal segments.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The primary end point was target lesion revascularization (TLR) at 1-year follow-up
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cumulative combined incidence of death and/or reinfarction at 2 year; Cumulative incidence of in-stent thrombosis at 2 year; 3) Major Adverse Cardiac Events (MACE) (combined death and/or reinfarction and/or TLR) at 2 years
Time Frame: 2 year
|
2 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Emilio Di Lorenzo, MD PhD, Division of Cardiology A.O. Moscati Avellino Italy
Publications and helpful links
General Publications
- Di Lorenzo E, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G, De Luca G. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. Am Heart J. 2009 Oct;158(4):e43-50. doi: 10.1016/j.ahj.2009.03.016.
- Di Lorenzo E, De Luca G, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. JACC Cardiovasc Interv. 2009 Jun;2(6):515-23. doi: 10.1016/j.jcin.2009.03.012.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AOM_DES01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.